No single antimicrobial treatment is superior in treating Clostridium difficile infections, according to a report from the Agency for Healthcare Research and Quality.
For this report, AHRQ researchers searched for relevant medical literature in MEDLINE, the Cochrane Library and Allied and Complementary Medicine. In addition, ClinicalTrials.gov and expert consultants provided leads to additional studies. Researchers also manually searched reference lists from relevant literature.
Their analysis revealed that the standard antibiotic treatments — oral vancomycin, metronidazole and the newly approved fidaxomicin — are equally effective for curing initial C. difficile infections. However, recurrence of these infections was less frequent for those who used fidaxomicin rather than vancomycin.
For this report, AHRQ researchers searched for relevant medical literature in MEDLINE, the Cochrane Library and Allied and Complementary Medicine. In addition, ClinicalTrials.gov and expert consultants provided leads to additional studies. Researchers also manually searched reference lists from relevant literature.
Their analysis revealed that the standard antibiotic treatments — oral vancomycin, metronidazole and the newly approved fidaxomicin — are equally effective for curing initial C. difficile infections. However, recurrence of these infections was less frequent for those who used fidaxomicin rather than vancomycin.
Related Articles on Clostridium Difficile:
California Health Department Releases Six Reports on Healthcare-Acquired Infections
Hospital-Acquired C. Difficile Could Increase Hospital Stays by 6 Days
Rochester Area Hospitals, BCBS Partner in Infection Prevention Collaboration